A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects With Diabetes, Dyslipidemia and Hypertension
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Omzotirome (Primary)
- Indications Cardiovascular disorders; Diabetes mellitus; Dyslipidaemias; Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Torrent Pharmaceuticals
- 16 Jul 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2022.
- 16 Jul 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2022.
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.